

CURRICULUM VITAE

Timothy T. You, M.D.

Fellow, American Academy of Ophthalmology

CA Medical License #G80625

Mailing/Contact Address:

Orange County Retina Medical Group

1200 North Tustin Avenue, Suite 140

Santa Ana, California 92705

714-972-8432

PROFESSIONAL PRACTICE AFFILIATIONS

Orange County Retina Medical Group
Physician/Surgeon/Partner/Clinical Trial Investigator
Since 3/1/2005

1200 North Tustin Avenue	Suite 140	Santa Ana, CA 92705	714-972-8432
1200 North Tustin Avenue	Suite 100	Santa Ana, CA 92705	714-972-8432
24022 Calle de la Plata	Suite 475	Laguna Hills, CA 92653	949-581-3618
320 Superior Avenue	Suite 160	Newport Beach, CA 92663	949-646-3242
333 W. Bastanchury Road	Suite 200	Fullerton, CA 92835	714-451-0801
31451 Rancho Viejo Road	Suite 101	San Juan Capistrano, CA 92675	949-496-0611

7/2002-2/2005 Rhode Island Eye Institute, Providence, Rhode Island

7/1999-6/2002 Pacific Clear Vision Institute, Eugene, Oregon

EDUCATION AND TRAINING

Vitreo-Retinal Fellowship

Massachusetts Eye and Ear Infirmary

Harvard Medical School, Boston, Massachusetts, 1997-1999

- Thomas Heed Ophthalmic Fellow, 1997-98
- American Ophthalmological Society, Herman Knapp Fellow, 1998-99

Residency in Ophthalmology

Massachusetts Eye and Ear Infirmary

Harvard Medical School, Boston, Massachusetts, 1994-1997

Internship in Medicine

VA Medical Center, Sepulveda, California

University of California, Los Angeles, 1993-1994

Research Fellowships

Penn Medical Scholars Anatomic Pathology Fellowship

Department of Pathology & Laboratory Medicine

Hospital of the University of Pennsylvania, 1991-1992

Children's Hospital of Los Angeles

University of Southern California, Doheny Eye Institute

Medical Student Fellowship in Pediatric Ophthalmology, 1989

Medical School

Medical Doctorate

University of Pennsylvania School of Medicine

University of Pennsylvania, Philadelphia, Pennsylvania, 1988-1993

Undergraduate Education

Bachelor of Science in Biology with distinction in major & *cum laude*
Yale College, New Haven, Connecticut, 1984-1988

Lab Assistant, Yale School of Medicine, Department of Microbiology, 1987

PROFESSIONAL POSITIONS

- 2013-Present Clinical Preceptor, Marshall B. Ketchum University, Southern California College of Optometry, Fullerton, California
- 2012-Present Preceptor and Site Coordinator/Assistant Clinical Professor, Western University Health Sciences, Pomona, California
- 2012-Present Chief, Department of Ophthalmology, Children's Hospital of Orange County, Orange, California
- 2012-Present Clinical Assistant Professor. Preceptor and Site Coordinator. Western University Health Sciences, Pomona, California
- 2009-Present Advisor, Clinical Institute, St. Joseph Hospital, Orange, California
- 2010-2012 Member, Planning Committee, Children's Hospital of Orange County Tower, Orange, California
- 2006-Present Expert Witness, Medical Board of California
- 2005-Present Medical Reviewer, MES Group
- 2003-2005 Assistant Clinical Professor in Ophthalmology, Brown Medical School, Providence, Rhode Island
- 2000-Present Medical Reviewer, Advanced Medical Group
- 1997-1999 Assistant Staff, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts

MEDICAL LICENSES

American Board of Ophthalmology, Diplomate, (Recertification) in 2009 (2009-2019)
Maintenance of Certification

American Board of Ophthalmology, Diplomate, (Recertification) in 2016 (2019-2029)
Maintenance of Certification

American Board of Ophthalmology, Diplomate, (Board Certified) in 1999
Exam score 95th percentile

American Board of Ophthalmology, Diplomate, (Recertification) in 2009
Maintenance of Certification

Diplomat National Board of Medical Examiners, since 1994

Medical Board of California, since 1993

HOSPITAL/SURGERY CENTER AFFILIATIONS

03/01/2005 – Present	Children’s Hospital at Mission, Mission Viejo, California
03/02/2005 – Present	Orange County Global Medical Center (formerly Western Medical Center, Santa Ana, California)
03/02/2005 – Present	Pacific Hills Surgery Center, Laguna Hills, California
04/01/2005 – Present	St. Joseph Hospital, Orange, California
04/21/2005 – Present	Children's Hospital of Orange County, Orange, California
05/20/2005 – Present	Hoag Memorial Hospital Presbyterian, Newport Beach, California
06/22/2005 – Present	Anaheim Regional Medical Center, Anaheim, California
09/22/2006 – Present	St. Jude Medical Center, Fullerton, California
11/2010 – Present	Barranca Surgery Center, Irvine, California

HONORS AND AWARDS

2019	Physician of Excellence Award, Orange County Medical Association, Orange Coast Magazine
2018	Physician of Excellence Award, Orange County Medical Association, Orange Coast Magazine
2017	Physician of Excellence Award, Orange County Medical Association, Orange Coast Magazine
2016	Physician of Excellence Award, Orange County Medical Association, Orange Coast Magazine
2016	Excellence in Teaching Award, Western School of Health Sciences
2015	Physician of Excellence Award, Orange County Medical Association, Orange Coast Magazine
2014	Physician of Excellence Award, Orange County Medical Association, Orange Coast Magazine
2003	Brown Medical School Award for Excellence in Teaching
1999	Fellow of the Year for Massachusetts Eye and Ear for Excellence in Teaching
1999	Fellow Award at Paul Chandler Lecture for Resident Teaching
1997	STORZ Ophthalmic Instrument Design Contest for Modified Phaco-Chopper
1994-1991	Bill Raskob Foundation Award
1993	History of Medicine Prize, <i>The Stigma of Atomic Bomb Disease</i>
1992	History of Medicine Prize, <i>A Short History of Egyptian Military Ophthalmia</i>
1989	Whanki Essay Contest, <i>The Perfect Painting</i> , second place
1988	Summer Research Internship, Taejon Research Institute, South Korea
1985	Jostens' Scholarship
1985	Elks Club Western-Division Scholarship
1985	Soroptomist Club Scholarship
1985	Orange County Medical Association Scholarship
1984-1988	Mission Community Hospital Auxiliary Scholarship
1982-1984	American Academy of Sciences Junior Scientist, University of Southern California/University of California at Irvine

PROFESSIONAL SOCIETY MEMBERSHIPS

American Academy of Ophthalmology, Fellow
American Society of Retina Specialists (The Vitreous Society)
Association for Research in Vision and Ophthalmology
California Association of Eye Physicians and Surgeons
California Medical Association
California Scholarship Federation
Orange County Society of Ophthalmology
Orange County Medical Association
Oregon Medical Association
Society of Heed Fellows
Society of Penn Medical Scholars
Western Retina Study Club

CLINICAL RESEARCH

01. Genentech, Inc., Protocol FVF2598g (MARINA), Phase IIIb; 2003-2005
Sub-Investigator. *A multicenter, randomized, double masked, sham injection-controlled study of the safety and efficacy of rhuFab V2 in subjects with neovascular AMD who have minimally classic or occult lesion*
02. Eyetech Pharmaceuticals, Protocol EOP1004, Phase II/III; 2005-2005
Sub-Investigator. *A randomized, double-masked, controlled, dose-ranging, multi-center comparative trial, in parallel groups, to establish safety and efficacy of intravitreal injections of EYE001 (anti-VEGF pegylated aptamer) in patients with exudative AMD*
03. Alcon Research, Ltd., Protocol C-01-99, Phase III; 2005-2005
Sub-Investigator. *A multicenter, double-masked, randomized, parallel groups study to demonstrate efficacy and safety of anecortave treatment relative to Visudyne for AMD*
04. OxiGENE, Inc., Protocol MMD-213, Phase III; 2005-2006
Sub-Investigator. *A multi-center, randomized, double-masked, placebo-controlled, parallel group, evaluation of the safety and efficacy of combretastatin A4 phosphate infusion for treating subfoveal CNV in pathologic myopia*
05. Diabetic Retinopathy Clinical Research Network(DRCR)/National Eye Institute, Protocol B; 2005-2009
Sub-Investigator. *A randomized trial comparing intravitreal corticosteroids and laser photocoagulation for DME*
06. Alcon Research, Ltd., Protocol C-02-60 (AART), Phase III; 2005-2009
Sub-Investigator. *Anecortave Acetate Risk Reduction Trial (AART): An evaluation of efficacy and safety of posterior juxtasclear administrations of anecortave acetate for depot suspension (15 mg or 30 mg) versus sham administration in patients (enrolled in study "A" or study "B") at risk for developing sight-threatening CNV due to exudative AMD*
07. National Eye Institute, SCORE; 2005-2009
Sub-Investigator. *The Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE): Two randomized trials to compare the efficacy and safety of intravitreal injection(s) of triamcinolone acetonide with standard care to treat macular edema: one for CRVO and one for BRVO*
08. Lilly ICOS LLC, Protocol H6D-MC-LVGO, Phase IV, Collaborative Study; 2005-2006
Sub-Investigator. *A randomized, double-blind, parallel-design, placebo-controlled study to evaluate the effects of 5mg tadalafil (IC351, LY450190) and 50mg sildenafil administered once daily for 6 months on visual function in healthy subjects or subjects with mild erectile dysfunction*
09. Alcon Research, Ltd., Protocol C0459 (IDEAA), Phase III; 2005-2007
Sub-Investigator. *A trial using anecortave acetate 15mg administered every 3 months versus anecortave acetate 15 mg every 6 months versus anecortave acetate 30 mg administered every 6 with exudative AMD*
10. Eyetech Pharmaceuticals, Protocol EOP1012, Phase IV; 2005-2007
Sub-Investigator. *A randomized, active-controlled, double-masked, single dummy, multicenter comparative trial, in parallel groups, to compare the safety and efficacy of intravitreal injections of Macugen given every 6 weeks for up to 102 weeks, plus sham PDT, to Macugen plus PDT with Visudyne, in subjects with predominantly classic subfoveal CNV secondary to AMD*

11. Novartis, Protocol CBPD952E2202 (VERITAS), Phase IIIB; 2005-2007
Principal Investigator. *A 24-month randomized, double-masked, sham controlled, multicenter study comparing PDT with verteporfin (Visudyne) plus two different dose regimens of intravitreal triamcinolone acetonide (1 mg and 4 mg) versus Visudyne plus intravitreal pegaptanib (Macugen) in patients with subfoveal CNV secondary to AMD*
12. (OSI) Eyetech, Protocol EOP1023 (LEVEL), Phase IV; 2006-2008
Principal Investigator. *An open label, multicenter trial of maintenance intravitreal injections of Macugen (pegaptanib sodium) given every six weeks for 48 weeks in subjects with subfoveal neovascular AMD initially treated with a different modality resulting in maculopathy improvement*
13. QLT Inc./RVT 002 (Registry II) (QUEST); 2006-2008
Sub-Investigator. *Registry for QLT using Visudyne in evaluation of sequential and triple therapies*
14. Novartis, Protocol #CBPD952A2308 (DENALI), Phase IIIB; 2006-2010
Principal Investigator. *A 24-month randomized, double-masked, controlled, multicenter study assessing safety and efficacy of verteporfin (Visudyne) photodynamic therapy administered in conjunction with ranibizumab (Lucentis) versus ranibizumab (Lucentis) monotherapy in patients with subfoveal CNV secondary to AMD*
15. Alimera Sciences, Protocol C-01-05-001 (FAME), Phase III; 2006-2011
Sub-Investigator. *Fluocinolone Acetonide in Diabetic Macular Edema (FAME): A randomized, double-masked, parallel group, multicenter, dose-finding comparison of the safety and efficacy of ASI-001A 0.5ug/day and ASI-001B 0.2 ug/day fluocinolone acetonide intravitreal inserts to sham injection in subjects with DME (Medidur®)*
16. Regeneron, Protocol VGFT-OD-0605 (VIEW 1), Phase III; 2006-2011
Sub-Investigator. *Clinical Evaluation of Anti-angiogenesis in the Retina - Intravitreal Trial 3 (CLEAR-IT 3): A randomized, double-masked, active-controlled phase III study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF Trap in subjects with neovascular AMD*
17. Opko, Protocol ACU-301 (COBALT), Phase III; 2007-2009
Sub-Investigator. *Combining Bevasirininib and Lucentis Therapy (COBALT): A randomized, double-masked, parallel-assignment study of intravitreal bevasirininib sodium, administered every 8 to 12 weeks as maintenance therapy following three injections of Lucentis compared with Lucentis monotherapy every 4 weeks in patients with exudative AMD*
18. Allergan, Protocol 206207-012, Phase III; 2007-2010
Sub-Investigator. *A 52-week, masked, multicenter, randomized, controlled trial (with up to 13 weeks additional follow-up) to assess the safety and efficacy of 700 ug dexamethasone posterior-segment drug delivery system (DEX PS DDS) Applicator System in combination with laser photocoagulation compared with laser photocoagulation alone in the treatment of subjects with diffuse DME*
19. Vitreoretinal Technologies, Inc., Protocol PVD-301, Phase III; 2007-2010
Sub-Investigator. *A safety and efficacy study of Vitreosolve for ophthalmic intravitreal injection for inducing posterior vitreous detachment in subjects with NPDR*
20. Merck & Co., Protocol 007-01, Collaborative Study; 2008-2009
Ophthalmology Investigator. *A safety follow-up study of patients previously exposed to MK-0634 (a beta-3 receptor antagonist developed for the treatment of overactive bladder). Subjects had previously been enrolled in a multicenter, double-blind, randomized, placebo-controlled, parallel group, dose-ranging study of L-000796568 in postmenopausal women with OAB*

21. Allergan, Protocol 206207-019-00, Phase II; 2008-2010
Sub-Investigator. *A 26-week, open-label study to assess the safety and efficacy of 700 ug dexamethasone posterior segment drug delivery system applicator system in conjunction with Lucentis® in the treatment of patients CNV secondary to AMD*
22. Ophthotech Corp., Protocol OPH3000, Phase I; 2008-2010
Sub-Investigator. *An ascending dose and parallel group trial to establish the safety, tolerability and pharmacokinetic profile of multiple intravitreal injections of volociximab ($\alpha 5\beta 1$ integrin antagonist) as monotherapy or in combination with Lucentis 0.5 mg/eye in subjects with neovascular AMD*
23. Regeneron, Protocol VGFT-OD-0706 (DA VINCI), Phase III; 2008-2011
Sub-Investigator. *A double-masked, randomized, controlled study of the safety, tolerability and biological effect of repeated intravitreal administration of VEGF Trap-eye in patients with DME*
24. NEI/Tufts Medical Center, The Family Study of Macular Degeneration; 2009-2010
The goal is to evaluate genetic and non-genetic risk factors for AMD
25. Allergan, Protocol 206207-018-00, Phase II; 2008 - 2010
Sub-Investigator. *A 26-week, open-label study to assess the safety and efficacy of 700 ug dexamethasone posterior segment drug delivery system applicator system in the treatment of vitrectomized subjects with DME*
26. Grunenthal, Protocol KF0151Y/10, Phase IIb, Collaborative Study; 2009-2011
Sub-Investigator. *A randomized, multicenter, double-blind, parallel-group trial to assess the analgesic efficacy and safety of a new analgesic compared with placebo in subjects with painful diabetic peripheral neuropathy*
27. Endo Pharmaceuticals, Protocol EN3324-201, Phase IIb, Collaborative Study; 2010-2011
Sub-Investigator. *A randomized, multicenter, double-blind, two-arm, multicenter, placebo-controlled study to assess the efficacy and safety of EN3324 (Axomadol) in subjects with moderate to severe chronic low back pain*
28. GlaxoSmithKline, Protocol MD 7110852, Phase IIB; 2009-2012
Principal Investigator. *A dose-ranging study of pazopanib eye drops vs. ranibizumab intravitreal injections for the treatment of neovascular AMD*
29. Genentech, Protocol FVF4579g (HARBOR), Phase III; 2009-2012
Sub-Investigator. *A double-masked, multicenter, randomized, active treatment-controlled study of the efficacy and safety of 0.5 mg and 2.0 mg ranibizumab administered monthly or on an as needed basis (PRN) in patients with subfoveal neovascular AMD*
30. Lux Biosciences, Inc., Protocol LX211-11, Phase III; 2011-2013
Sub-Investigator. *A multicenter, double-masked, parallel group, placebo-controlled study to assess the efficacy and safety of Voclosporin as therapy in subjects with active noninfectious intermediate, posterior or pan-uveitis*
31. Lpath, Protocol LT1009-Oph-003 (NEXUS), Phase IIA; 2011-2015
Sub-Investigator. *A multicenter, masked, randomized, comparator-controlled study evaluation Isonep™ (sonenpcizumab [LT1009]) as either monotherapy or adjunctive therapy to Lucentis or Avastin versus Lucentis or Avastin alone for the treatment of subjects with choroidal neovascularization secondary to AMD*
32. Alimera, Protocol C-01-11-008, FAME Extension Study; 2011-2013
Sub-Investigator. *An open-label, multicenter, extension study of the safety and utility of the new inserter of Iluvien® (Fluocinolone Acetonide Intravitreal Insert) 0.19mg and the safety of Iluvien® in subjects with DME*

33. EyeGate Pharmaceuticals, Protocol EGP-437-004, Phase III; 2012-2013
Sub-Investigator. *A prospective, multi-center, randomized, double-masked, positive controlled, clinical trial designed to evaluate the safety and efficacy of iontophoretic dexamethasone phosphate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis*
34. Quark Pharmaceuticals, Protocol QRK202 (MATISSE); Phase II, 2012-2013
Sub-Investigator. *An open-label dose escalation study of PF-04523655 (Stratum I) combined with a prospective, randomized, double-masked, multi-center, controlled study (Stratum II) evaluating the efficacy and safety of PF-04523655 alone and in combination with ranibizumab versus ranibizumab alone in diabetic macular edema*
35. Xoma, Protocol X052130/CL3-78989-005 (EYEGUARD™ -A), Phase III; 2012-2015
Principal Investigator. *A randomized, double-masked, placebo-controlled study of the safety and efficacy of gevokizumab in the treatment of active non-infectious intermediate, posterior, or pan-uveitis*
36. Pfizer, Protocol B1181003-1050 (“DREAM”), Phase II; 2012-2013
Sub-Investigator. *A phase 2, multi-center, randomized, double-masked, placebo-controlled, multi-dose study to investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of RN6G (PF-04382923) in subjects with geographic atrophy secondary to age-related macular degeneration*
37. Xoma, Protocol X052131/CL3-78989-005 (EYEGUARD™ -C), Phase III; 2012-2015
Principal Investigator. *A randomized, double-masked, placebo-controlled study of the safety and efficacy of gevokizumab in the treatment of subjects with non-infectious intermediate, posterior, or pan-uveitis currently controlled with systemic treatment*
38. Regeneron, Protocol VGFTe-AMD-1124 (RE-VIEW), Phase IV; 2012-2015
Sub-Investigator. *Rigorous evaluation of vision and safety with intravitreal aflibercept injection dosed every 8 weeks over 2 years in neovascular AMD*
39. Merck, Protocol MK8931-017 (SCH 900931, P07738) (EPOCH), Phase 2/3, Collaborative Study; 2012-Present
Ophthalmology Investigator. *A randomized, placebo controlled, parallel-group, double blind efficacy and safety trial of MK-8931 in subjects with mild to moderate Alzheimer's disease*
40. Ophthotech, Protocol OPH1003 (ELCIPSE), Phase III; 2013-2017
Sub-Investigator. *A randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista™ (Anti-PDGF-B pegylated aptamer) administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal neovascular macular degeneration*
41. Allergan, Protocol GMA-OZU-13-598 (ECHO), Retrospective Registry; 2013-2014
Sub-Investigator. *A retrospective data collection study in patients receiving anti-VEGF injections for retinal vein occlusion or diabetic macular edema*
42. Aerpio, Protocol AKB-9778-CI-2003 (TIME 2), Phase II; 2014-2015
Sub-Investigator. *A phase 2, randomized, active-controlled, double-masked, multicenter study to assess the safety and efficacy of daily subcutaneous AKB-9778 administered for 3 months, as monotherapy or adjunctive to ranibizumab, in subjects with diabetic macular edema*
43. Xoma, Protocol X052132 (EYEGUARD™ -E), Phase III; 2014-2015
Principal Investigator. *An open-label, non-randomized, single-arm, roll-over study to continue dosing of gevokizumab in non-infectious intermediate, posterior, or pan-uveitis patients who each successfully completed either the X052130 or the X052131 study*

44. Merck, Protocol MK8931-019 (APECS), Phase III, Collaborative Study; 2014-2018
Ophthalmology Investigator. *A phase III, randomized, placebo-controlled, parallel-group, double blind clinical trial to study the efficacy and safety of MK8931 (SCH900931) in subjects with amnesic mild cognitive impairment due to Alzheimer's Disease (Prodromal AD)*
45. National Eye Institute, SCORE2, Phase III; 2014-2016
Sub-Investigator. *A multicenter, prospective, randomized non-inferiority trial of eyes with macular edema secondary to central retinal vein occlusion, comparing intravitreal bevacizumab every 4 weeks with intravitreal aflibercept every 4 weeks*
46. Allergan, Protocol #150998-004 (PALM), Phase II; 2014-2015
Sub-Investigator. *Evaluation of Abicipar Pegol (AGN-150998) in patients with decreased vision due to diabetic macular edema*
47. Thrombogenics, Protocol #TG-MV-018 (ORBIT), Prospective Registry, Phase IV; 2014-2016
Sub-Investigator. *Ocriplasmin Research to Better Inform Treatment*
48. Thrombogenics, Protocol #TG-MV-022 (OZONE), Retrospective Registry, Phase IV; 2014-2015
Sub-Investigator. *Ocriplasmin Ellipsoid Zone Retrospective Data Collection Study*
49. Allergan, Protocol #GMA-US-EYE-0272(REINFORCE), Prospective Registry, Phase IV; 2014-2016
Sub- Investigator. *The Ozurdex Diabetic Macular Edema Patient Registry*
50. Hoffmann-La Roche, Protocol #GX29176 (CHROMA), Phase III; 2014-2018
Sub-Investigator. *A randomized, double-masked, sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patients with geographic atrophy secondary to age-related macular degeneration*
51. Xoma, Protocol X052133 (EYEGUARD™ -US), Phase III; 2015-2015
Principal Investigator. *A randomized-withdrawal, double-masked, placebo-controlled study of the efficacy and safety of gevokizumab in treating subjects with Behçet's disease uveitis*
52. Allegro Ophthalmics, Protocol DME-202B (DEL MAR), Phase II; 2015-2015
Sub-Investigator. *A phase 2, multicenter, randomized, controlled, double-masked clinical trial designed to evaluate the safety and exploratory efficacy of Luminata® (ALG-1001) as compared to Avastin® and focal laser photocoagulation in the treatment of diabetic macular edema*
53. Iconic Therapeutics, Protocol IT-002 (EMERGE), Phase II; 2015-2016
Sub-Investigator. *A phase 2, randomized, double-masked, multicenter, active-controlled study evaluating administration of repeated intravitreal doses of hI-con1™ in patients with choroidal neovascularization secondary to age-related macular degeneration*
54. Bayer, Protocol BAY 73-4506/15984 (DREAM), Phase IIa/IIb; 2015-2015
Principal Investigator. *A combined phase IIa/IIb study of the efficacy, safety and tolerability of repeated topical doses of regorafenib eye drops, in treatment-naïve subjects with neovascular age-related macular degeneration*
55. Allergan, Protocol 150998-005 (CEDAR), Phase III; 2015-Present
Sub-Investigator. *A multicenter, randomized, double-masked, parallel-group, active-controlled study evaluating the safety and efficacy of abicipar pegol (AGN-150998) in patients with neovascular age-related macular degeneration*
56. Ophthotech, Protocol OPH1004, Phase III; 2015-2016
Sub-Investigator. *A phase 3, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista (anit PDGF-B pegylated aptamer) administered in combination with either Avastin or Eylea compared to Avastin or Eylea monotherapy in subjects with subfoveal neovascular age-related macular degeneration*

57. Ophthotech, Protocol OPH1005 Phase III; 2015-2016
Sub-Investigator. *A 24 month, phase 2a, open label, safety study of Fovista (anti-PDGF-BB pegylated aptamer) regimen administered in combination with anti-VEGF therapy (Avastin, Eylea, or Lucentis) during the induction and maintenance phase of therapy*
58. Ophthotech, Protocol OPH1006 Phase III; 2015-2017
Sub-Investigator. *Effect of anti-VEGF agents administered on a quarterly maintenance regimen in subjects with neovascular AMD receiving anti-PDGF therapy: An 18-month, phase 2a, open-label, randomized study of Avastin, Lucentis, or Eylea (anti-VEGF therapy) administered in combination with Fovista (anti-PDGF BB pegylated aptamer)*
59. Regeneron, Protocol R2176-3-AMD-1417 (CAPELLA), Phase II; 2015-2017
Sub-Investigator. *A phase 2, double-masked, randomized, controlled, multiple-dose, regimen-ranging study of the efficacy and safety of intravitreal REGN2176-3 in patients with neovascular age-related macular degeneration*
60. Astellas, Protocol 8232-CL-3001 (VIDI), Phase III; 2015-2016
Sub-Investigator. *A phase 2, double-masked, randomized, active controlled study to evaluate the efficacy and safety of ASP8232 in reducing central retinal thickness in subjects with diabetic macular edema*
61. Alcon, Protocol RTH258-C001 (HAWK), Phase III; 2015-2018
Sub-Investigator. *A two-year, randomized, double-masked, multicenter, three-arm study comparing the efficacy and safety of RTH258 versus aflibercept in subjects with neovascular age-related macular degeneration*
62. Clearside Biomedical Protocol #CLS1001-301 (PEACHTREE), Phase III; 2015-2018
Principal Investigator. *A phase 3, randomized, masked, controlled clinical trial to study the safety and efficacy of triamcinolone acetate injectable suspension (CLS-TA) for the treatment of subjects with macular edema associated with non-infectious uveitis*
63. Genentech/Roche, Protocol #GX28228 (LADDER), Phase II; 2016-Present
Sub-Investigator. *A phase II, multicenter, randomized, active treatment-controlled study of the efficacy and safety of the ranibizumab port delivery system for sustained delivery of ranibizumab in patients with subfoveal neovascular AMD*
64. Alimera, Protocol #M-01-15-004 (PALADIN), Phase IV; 2016-Present
Sub-Investigator. *A phase IV safety study of IOP signals in patients treated with Iluvien (fluocinolone acetate intravitreal implant) 0.19mg*
65. Arctic Diagnostics, Protocol #AMD SCI-GEN, Observational Registry, 2016-2018
Site Investigator. *AMD study of the clinical impact of genetics*
66. ThromboGenics, Protocol #TG-MV-015 (CIRCLE), Phase II; 2016-Present
Principal Investigator. *phase 2, randomized, double-masked, sham-controlled, multi-centre study to evaluate the efficacy and safety of ocriplasmin in inducing total posterior vitreous detachment (PVD) in subjects with non-proliferative diabetic retinopathy (NPDR)*
67. L. Hoffmann-La Roche, Protocol #BP29647 (AVENUE), Phase II; 2016-2018
Sub-Investigator. *A multiple-center, multiple-dose and regimen, randomized, active comparator controlled, double-masked, parallel group, 36 week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of R06867461 administered intravitreally in patients with choroidal neovascularization secondary to age-related macular degeneration*

68. L. Hoffmann-La Roche, Protocol #BP30099 (BOULEVARD), Phase II; 2016-2018
Sub-Investigator. *A multiple-center, multiple-dose, randomized, active comparator-controlled, double-masked, parallel group, 36-week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of R06867461 administered intravitreally in patients with diabetic macular edema*
69. Actelion, Protocol #ACT-058B301 (OPTIMUM), Phase III Collaborative Trial; 2016-Present
Sub-Investigator. *Multicenter, randomized, double-blind, parallel-group, active-controlled, superiority study to compare the efficacy and safety of ponesimod to teriflunomide in subjects with relapsing multiple sclerosis*
70. Eli Lilly, Protocol I7X-MC-LLCF (NAVIGATE-AD), Phase II Collaborative Trial; 2016-2018
Ophthalmology Investigator. *Effect of LY3202626 on alzheimer's disease progression as measured by cerebral 18 F-AV-1451 Tau-PET in mild alzheimer's disease dementia*
71. Clearside, Protocol #CLS1001-303 (MAGNOLIA), Phase III; 2017-2018
Principal Investigator. *A phase 3, randomized, masked, controlled clinical trial to study the safety and efficacy of triamcinolone acetonide injectable suspension (CLS-TA) for the treatment of subjects with macular edema associated with non-infectious uveitis*
72. Genentech/Roche, Protocol #GX30191 (OMASPECT), Phase IIIb; 2017-2018
Sub-Investigator. *A multicenter, open-label extension study to evaluate the long-term safety and tolerability of lampalizumab in patients with geographic atrophy secondary to age-related macular degeneration who have completed a Roche-sponsored study*
73. Clearside, Protocol #CLS1003-301 (SAPPHIRE), Phase III; 2017-2019t
Principal Investigator. *A randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in conjunction with intravitreal aflibercept in subjects with retinal vein occlusion*
74. Regenerative Patch Technologies, Protocol #RPT-14-001, Phase I; 2017-Present
Sub-Investigator. *A phase I/IIA safety study of subretinal implantation of CPCB-RPE1 (human embryonic stem cell-derived retinal pigment epithelial (RPE) cells seeded on a polymeric substrate) in subjects with advanced, dry age-related macular degeneration (AMD)*
75. VisionCare, Protocol #IMT-TES-2016, Phase IV; 2017-Present
Sub-Investigator. *A prospective, multicenter clinical trial of the implantable miniature telescope in pseudophakic eyes with central vision impairment associated with end-stage macular degeneration. TES Study: Telescope Exchange Study*
76. Regeneron, Protocol #VGFTe-OD-1411 "PANORAMA", Phase III; 2017-2017
Sub- Investigator. *A phase 3, double-masked , randomized study of the efficacy and safety of intravitreal aflibercept injection in patients with moderately severe to sever non-proliferative diabetic retinopathy*
77. Allergan, Protocol #VOLUMA-007 "VOLUMA" Collaborative Study, Phase IV; 2017-2017
Ophthalmology Investigator. *A multicenter, single-blind, randomized, parallel-group, controlled study of the safety and effectiveness of JUVÉDERM VOLUMA® XC injectable gel for correction of temple hollowing*
78. Aldeyra, Protocol #ADX-102-UV-005, Phase III; 2017-Present
Principal Investigator. *A phase 3 randomized, double-masked, vehicle-controlled trial to evaluate the safety and efficacy of ADX-102 ophthalmic solution in subjects with non-infectious anterior uveitis*
79. Ophthotech, Protocol #OPH2007, Phase II; 2017-2019
Sub-Investigator. *A phase 2A open-label trial to assess the safety of Zimura™ (anti-C5) administered in combination with Lucentis· 0.5mg in treatment naïve subjects with neovascular age-related macular degeneration*

80. Opthea, Protocol #OPT-302-1002, Phase III; 2017-Present
Sub-Investigator. *A dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD)*
81. Ophthotech, Protocol #OPH2003, Phase II/III; 2017-Present
Sub-Investigator. *A phase 2/3 randomized, double-masked, controlled trial to assess the safety and efficacy of intravitreal administration of Zimura™ (Anti-C5 Aptamer) in subjects with geographic atrophy secondary to dry age-related macular degeneration*
82. Opthea #OPT 302-1003, Phase IB/IIA; 2017-Present
Sub-Investigator: *Phase 1b/2a study of OPT-302 in combination with aflibercept for persistent center-involved diabetic macular edema*
83. Genentech, Protocol GX28228 “LADDER” Sub-Study (OAT), Phase II; 2017-Present
Sub-Investigator. *Oral antithrombotic therapy substudy in association with study GX28228: A phase II, multicenter, randomized, active treatment-controlled study of the efficacy and safety of the Ranibizumab Port Delivery System for sustained delivery of Ranibizumab in patients with subfoveal neovascular age-related macular degeneration*
84. KalVista, Protocol KVD001-2001, Phase II; 2018-Present
Sub-Investigator. *A randomized, sham-controlled double-masked Phase 2a study of the efficacy, safety and tolerability of the intravitreal plasma kallikrein inhibitor, KVD001, in subjects with center-involving diabetic macular edema (ciDME) who have had prior anti-vascular endothelial growth factor (VEGF) treatment*
85. Iconic, Protocol IT-004 (DECO), Phase II; 2018-Present
Sub-Investigator: *A phase 2 randomized, open-label, multicenter study evaluating administration of repeated intravitreal doses of ICON-1 in patients with choroidal neovascularization secondary to age-related macular degeneration*
86. Eli-Lilly, Protocol #15T-MC-AACG (TRAILBLAZER), Phase III, Collaborate Study; 2018-Present
Ophthalmology Investigator. *Assessment of safety, tolerability and efficacy of LY3002813 alone and in combination with LY3202626 in early symptomatic alzheimer's disease*
87. Genentech/Roche, Protocol #GR40349 (YOSEMITE), Phase III; 2018-Present
Sub-Investigator. *A phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the simultaneous blockade of antiangiogenic factors VEGF-A and Angiopoietin-2 with the bispecific antibody RO6867461 (RG7716) in diabetic retinopathy patients with diabetic macular edema*
88. Genentech/Roche, Protocol #GR40549 (PORTAL), Phase III; 2018-Present
Sub-Investigator. *A multicenter, open-label extension study to evaluate the long-term safety and tolerability of the port delivery system with ranibizumab in patients with neovascular age-related macular degeneration*
89. Genentech/Roche, Protocol #GR40548 (ARCHWAY), Phase III; 2018-Present
Sub-Investigator. *A phase III, multicenter, randomized, visual assessor-masked, active-comparator study of the efficacy, safety and pharmacokinetics of the port delivery system with ranibizumab in patients with neovascular age-related macular degeneration*
90. Apellis, Protocol #APL2-304 (OAKS), Phase III; 2018-Present
Principal Investigator. *A phase III, multicenter, randomized, double-masked, sham-controlled study to compare the efficacy and safety of intravitreal APL-2 therapy with sham injections in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)*

91. Genentech, Protocol #GR40844 (LUCERNE), Phase III; 2019-Present
Sub-Investigator. *A phase III, multicenter, randomized, double-masked, active comparator, controlled study to evaluate the efficacy and safety of farcimab in patients with neovascular age-related macular degeneration*

ABSTRACTS

01. Wong CG, **You TT**, Ghosen C, Ton L, You L, Burke J, Wheeler L. *Experimental CNV in Cynomolgous monkey after sustained release of VEGF & bFGF within the suprachoroidal space.* Association for Research in Vision and Ophthalmology Meeting; May 2011. Abstract
02. Wong CG, **You TT**, Carvalho RAP. Natural history of progressive experimental CNV in the rabbit after sustained release of both VEGF and bFGF within the supra-choroidal space. Association for Research in Vision and Ophthalmology Meeting, May 2009. Abstract
03. Wong CG, Bruce TC, **You TT**. Experimental CNV after transcleral implantation of VEGF/bFGF-implant within the suprachoroidal space for defining potential long-term synergistic actions of ranibizumab (Lucentis) with small low-cost molecules in ameliorating wet AMD. Association for Research in Vision and Ophthalmology Meeting, May 2008. Abstract
04. **You TT**, Wong CG, Fedoruk T, Bonakdar M. Comparison of Lucentis and Avastin in the suprachoroidal VEGF/bFGF-implant rabbit CNV model provides a potential standardized pre-clinical approach in the rational development of more effective QSAR-based drugs, sustained release formulations, and drug delivery systems for ameliorating AMD. Association for Research in Vision and Ophthalmology Meeting, 2007. Abstract
05. Gupta G, Donahue JP, Andorsky S, **You TT**. Profile of the retina by optical coherence tomography in the pediatric age group. Association for Research in Vision and Ophthalmology, Ft. Lauderdale, Florida; May 1, 2005. Abstract
06. Gupta G, and **You TT**. Vitreous Hemorrhage in age-related macular degeneration. New England Ophthalmological Society, Boston, Massachusetts; May 2004. Abstract
07. **You TT** and Itturiaga J. "The Range of Abnormalities in *Drosophila* 1(1)ts-726 after High Temperature Shock Treatments." California Academy of Science Meeting, Los Angeles, California; 1984. Abstract
08. **You TT** and Itturiaga J. "Variations in Bristle Pattern After High Temperature Treatment in *Drosophila melanogaster*." American Academy of Science Meeting, New York, New York; 1984. Abstract

PAPERS AND PUBLICATIONS

01. **You TT**, Huang CX, Chen S, Maggiano JM, Rathod RR, Chang E, Casiano ME. Extreme patient positioning for retinal surgery in advanced kyphosis. (Submitted Aug2014, *Retinal Cases & Brief Reports*)
02. **You TT**, Youn DW, Chen S, Alexandrescu B, Casiano ME, Maggiano JM. Unusual ocular injury by an acupuncture needle. *Retinal Cases & Brief Reports*: Spring 2014; Vol.8: Issue 2:116-119.
03. Ambati J, Gragoudas ES, Miller JW, **You TT**, Miyamoto K, Delori FC, Adamis AP. Transscleral delivery of bioactive protein to the choroid and retina. *Invest Ophthalmol Vis Sci* 2000 Apr; 41(5):1186-91.
04. Arroyo JG, **You TT**, Bossi KE. Illuminated lens fixator for bimanual pars plana lensectomy. *Ophthalmic Surg Lasers* 2001 Sep-Oct; 32(5):438-40.

05. Rumeldt S, **You TT**, Remulla HD, Rubin PAD, Jakobiec FA. Prepartum mixed type cavernous-capillary hemangioma arising in nevus flammeus. *Ophthalmology* 1999;106:1219-22.
06. **You TT** and Power W. Choroidal detachments and uveal effusion syndrome. In: *Principles and Praxis of Ophthalmology* Vol. 2. Albert DM & Jakobiec F (eds). Saunders. Philadelphia. 1999;1338-1351.
07. **You TT** and JG. Arroyo. Surgical approaches to managing the dislocated crystalline lens. *Int Ophthalmol Clinics* 1999;39:1-12.
08. **You TT** and Kaiser PK, Netland PA, Jakobiec FA. Neurothekeoma palpebrae: a rare nerve sheath tumor arising in the eyelid. *Ophthal Plast Reconstr Surg.* 1999;6:448-9.
09. **You TT** and Young LHY. Retinal manifestations of gastrointestinal disorders. *Int Ophthalmol Clinics* 1998;38:197-220.
10. **You TT**, et al. Corneal Abrasion Patching Study Group. A study of topical nonsteroidal anti-inflammatory drops and no pressure patching in the treatment of corneal abrasions. *Ophthalmol* 1997; 104: 1353-59.
11. **You TT** and Pavan-Langston D. Chronic unilateral keratitis in a young man. *Dig J Ophthalmol* 1995 October 25;Vol. 1. Issue 2.
12. **You TT** and Dohlman CH. Progressive corneal opacification and arthropathy. *Dig J Ophthalmol* 1995 August 12;Vol. 1, Issue 1.
13. **You TT**, Choi JC, Partington MA, Whitaker LA, Shore JW. "Ophthalmic Findings Associated with Unilateral Non-compensational Plagiocephaly." Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida; 1995. Abstract
14. **You TT** and Pavan-Langston D. Immune reactions in corneal herpetic disease. *Int Ophthalmol Clinics* 1996;36: 31-39.
15. Menzin AW, **You TT**, Deger RB, J.J. Brooks, S.A. King. Sarcoidosis in a uterine leiomyoma. *Int J Gynaecol Obstet* 1995;48: 79-84.
16. Trojanowski JQ, Mantione JR, Lee JH, Seid DP, **You TT**, Inge LJ, Lee VMY. Neurons derived from a human teratocarcinoma cell line establish molecular and structural polarity following transplantation into the rodent brain. *Exp Neurology* 1993;122: 283-94.

POSTERS AND PRESENTATIONS

01. *New Treatment Paradigm Series: New Molecule for the Treatment of DME*
Speaker. Genentech Protocol #GR40349 "YOSEMITE", Irvine, California; March 7, 2019.
02. *New Treatment Paradigm Series: Surgically Implanted Ranibizumab Reservoir for Wet AMD*
Speaker. Genentech Protocol #GR40548 "ARCHWAY", Newport Coast, California; February 28, 2019.
03. *New Treatment Paradigm Series: Surgically Implanted Ranibizumab Reservoir for Wet AMD*
Speaker. Genentech Protocol #GR40548 "ARCHWAY", Newport Beach, California; February 26, 2019.
04. *New Treatment Paradigm Series: Novel Therapy for Non-Infectious Anterior Uveitis*
Speaker/Principal Investigator. Aldeyra Therapeutics Protocol #ADX-102-UV-005, Newport Beach, California; February 12, 2019.

05. *Retina Case Presentations*
Course Director. Orange County Global Medical Center, Santa Ana, California; February 4, 2019.
06. *Retina Case Presentations*
Course Director. Orange County Global, Santa Ana. California; November 13, 2018.
07. *Ocular Trauma*
Invited Speaker. Coastal Vision Symposium. Veterans Administration Medical Center, Long Beach, California; September 9, 2018.
08. *New Treatment Paradigm Series: Novel Biologic Therapy for Wet AMD*
Speaker. Iconic Therapeutics Protocol #IT-004, Newport Beach, California; August 29, 2018.
09. *Managing Common Retinal Disorders: A Nuts and Bolts Approach*
Invited Speaker. Orange County Optometric Society Pathology Symposium. Orange County Mining, Orange, California; August 19, 2018.
10. *Ophthotech Zimura anti-C5 for Neovascular AMD*
Speaker. Costa Mesa, California; August 2018.
11. *Top 5 Retinal Diagnoses You Don't Want to Miss and Adventures in the Operating Room*
Invited Speaker. Coastal Vision Symposium, Costa Mesa, California; July 17, 2018.
12. *Diabetic Retinal Diseases*
Invited Faculty. 2018 Indian Health System. Ketchum Health, Fullerton, California; June 5, 2018.
13. *Primer on Macular Diseases*
Invited Faculty. 2018 Indian Health System. Ketchum Health, Fullerton, California; June 5, 2018.
14. *Retinal Caratopathies*
Invited Speaker. Coastal Vision: 5th Annual Taste of the Islands Annual Symposium; May 6, 2018.
15. *New Treatment Paradigm Series: Novel Therapy for Non-Infectious Uveitis*
Principal Investigator. Aldeyra Therapeutics Protocol #ADX-102-UV-005, Newport Beach, California; March 21, 2018.
16. *Updates in Retina. Mystery Case: Patience is a Virtue*
Invited Speaker. Orange County Optometric Society: Antonello's Ristorante, Costa Mesa, California; February 26, 2018.
17. *Cases in Retinal Management*
Invited Speaker. Coastal Vision Symposium. Irvine, California; February 21, 2018.
18. *Rethinking Central Serous Chorioretinopathy*
Invited Speaker. JT Schmid's, Orange, California; January 30, 2018.
19. *New Treatment Paradigm Series: Suprachoroidal Therapy for Retinal Vein Occlusion*
Clearside Biomedical Protocol #CLS1003-301., Newport Beach, California; August 30, 2017.
20. *White Dot Syndrome*
Speaker. Pelican Hill, Newport Beach, California; August 30, 2017.
21. *Retina Case Presentations: Updates in AMD*
Course Director. Orange County Global Medical Center, Santa Ana. California; July 31, 2017.

22. *Faces of Age-Related Macular Degeneration*
Invited Speaker. Coastal Vision Symposium. Veterans Administration Medical Center, Long Beach, California; July 30, 2017.
23. *Regeneron Panorama Clinical Trial*
Speaker. Newport Beach, California; July 12, 2017.
24. *Regeneron Panorama Clinical Trial*
Speaker. Anaheim, California; July 11, 2017.
25. *New Treatment Paradigm Series: Stem Cell Patch for Severe Vision Loss*
Regenerative Patch Technologies Protocol #RPT-14-01. Newport Beach, California; June 1, 2017.
26. *Primer on Retinal Diseases*
Invited Speaker. Primer of Retinal Care and Diseases. Westminster College. Phnom Penh, Cambodia; May 18, 2017.
27. *Orange County Optometric Society. The Art of Retinal Surgery*
Invited Speaker. Costa Mesa, California; April 10, 2017.
28. *5 Retinal Diagnoses You Don't Want to Miss.*
Invited Speaker. 4th Annual Taste of the Islands Eye Conference. Hyatt Hotel. Huntington Beach. California; March 30, 2017.
29. *A Culinary Guide to Ophthalmic Diseases*
Invited Speaker. Orange County Optometric Society. Maggiano's, Costa Mesa, California; March 3, 2017.
30. *Surgical Advances in Retina and A Curious Case of Diabetes*
Speaker. Allergan Clinical Exchange Program. Watergrill, Costa Mesa, California; February 18, 2017.
31. *Retina Case Presentations*
Course Director. Orange County Global, Santa Ana. California; February 13, 2017.
32. *A Multidisciplinary Approach to Management of Diabetic Eye Disease*
Course Director. Allergan Clinical Exchange Program. Costa Mesa, California; November 17, 2016.
33. *New Treatment Paradigm? Iontophoretic Dexamethasone for Anterior Uveitis*
Eyegate Protocol #EGP-437-006 Study. Newport Beach, California; October 6, 2016.
34. *Updates in Retina: The Art of Scleral Depression*
Invited Speaker. Coastal Vision Symposium. Fullerton, California; August 30, 2016.
35. *Surgically Implanted Ranibizumab Reservoir for Wet AMD*
Speaker. Genentech/Roche Protocol #GX28228 "LADDER" Study. Anaheim, California; August 24, 2016.
36. *Retina Case Presentations*
Course Director. Orange County Global Medical Center, Santa Ana. California; August 9, 2016.
37. *CentraSight Implantable Miniature Telescope Exchange*
Guest Speaker. Hilton Hotel. Newport Beach, California; July 27, 2017.
38. *Novel Technique: Suprachroidal Drug Treatment for Uveitic Macular Edema*
Principal Investigator. Clearside Biomedical Protocol #CLS1001-301 "PEACHTREE" Study. Anaheim, California; June 1, 2016.

39. *Beyond Anti-VEGF: New Drug Molecule for Wet AMD*
Allergan Protocol #150998-005 “CEDAR” Study. Costa Mesa, California; July 21, 2016.
40. *What Happened on Flight 1331: Laser Induced Retinal Injury*
Invited Speaker.. NVision Annual Symposium. Anaheim, California; June 5, 2016.
41. *Novel Technique: Suprachroidal Drug Treatment for Uveitic Macular Edema*
Principal Investigator. Clearside Biomedical Protocol #CLS1001-301 “PEACHTREE” Study. Anaheim, California; June 1, 2016.
42. *Case of Bird Injury*
Speaker. A Wine Colony Merchant, Orange, California; June 1, 2016.
43. *New Treatment Paradigm Series: Suprachroidal Drug Treatment for Retinal Vein Occlusion*
Principal Investigator. Clearside Protocol #CLS1001-303 “SAPPHIRE” Wine Colony Merchant, Orange, California; June 1, 2016.
44. *Retinal Consideration for Cataract Surgery Co-Management*
Invited Speaker. Coastal Vision. Fullerton, California; May 25, 2016.
45. *A Culinary Guide to Ophthalmic Diseases*
Invited Speaker. Asian American Optometric Society 2016 Honors Symposium. Orange, California; May 15, 2016.
46. *Case Presentation: Clinical Case of Egret (R)egret*
Invited Speaker. 3rd Annual Taste of the Islands Eye Conference. Hyatt, Costa Mesa, California; April 17, 2016.
47. *Approach to Retina Surgery*
Invited Speaker. Pacific Hills Surgical Center. Laguna Hills, California; March 18, 2016.
48. *Speaker Considerations for Refractive Surgery: Retina Care of Myopic Patient*
Invited. Coyote Hills County Club. Fullerton, California; February 25, 2016.
49. *Advances in Surgical Retina*
Invited Speaker. Orange County Optometric Society. Costa Mesa, California; February 8, 2016.
40. *New Treatment Paradigm Series: Potential New Treatment for Dry AMD, Mechanism of Action*
Speaker. Roche/Genentech CHROMA Study. Newport Beach, California; October 29, 2015.
41. *Essentials of Ophthalmology and Retinal Surgery*
Invited Speaker. Bethel Silver Medical Missions Group. Villa Park, California; October 18, 2015.
42. *Beyond Anti-VEGF: New Drug Molecule for Wet AMD: Phase I Results*
Speaker. Allergan CEDAR Study., Costa Mesa, California; September 30, 2015.
43. *Elements of Retina Care*
Invited Speaker. Guatemala City, Guatemala; August 23, 2015.
44. *Updates in AMD: The Value of a Drop*
Invited Speaker. NVision Symposium, Anaheim, California; June 7, 2015.
45. *New Biologic Therapy for Behçet’s Disease: Behçet’s Case*
Principal Investigator. Xoma Clinical Study. Santa Ana, California; April 1, 2015.

46. *Understanding Pediatric Retinal Diseases*
Invited Speaker. 2nd Annual Taste of the Islands Eye Conference. Hyatt Hotel. Huntington Beach, California; March 26, 2015.
47. *New Technologies*
Invited Speaker. New Technologies Symposium: Macular Degeneration, Laguna Woods, California; March 31, 2015.
48. *Retinal Surgical Advances*
Course Director. Orange County Optometric Society, Orange, California; February 10, 2015.
49. *Adventures in the OR: Extreme Retinal Surgery*
Invited Guest Speaker. Orange, California; February 10, 2015.
50. Course Director. Retinal Case Conference, Ketchum University, Fullerton, California; February 9, 2015.
51. *Diabetic Macular Edema: Telemedicine*
Multidisciplinary Approach for Management of Patients with Diabetic Macular Edema, Irvine, California; September 10, 2014.
52. *Updates in Retinal Surgical Care*
Guest Speaker. Annual Pathology Symposium, Orange County Optometric Society, Irvine, California; August 10, 2014.
53. *Retinal Case Presentations*
Speaker. Retina Clinical Exchange for Orange County Ophthalmologists, Newport Beach, California; March 20, 2014.
54. *Updates in Macular Degeneration and Implantable Miniature Telescope*
Guest Speaker. AMD Symposium, Anaheim, California; February 11, 2014.
55. *Updates in Retina Care: Macular Degeneration and Implantable Miniature Telescope*
Course Director. Retina Care Symposium, Costa Mesa, California; December 5, 2013.
56. *Healthcare*
Invited Speaker. Third Annual Yorba Linda High School Career Day, Yorba Linda, California; November 13, 2013.
57. *Updates in Macular Degeneration*
Invited Speaker (JCAPHO). South Coast Eye Center, Laguna Hills, California; November 8, 2013.
58. *Cataract Surgery: Retinal Perils, Risks and Complications*
Invited Speaker. NVision Centers, Costa Mesa, California; August 22, 2013.
59. *Understanding Pediatric Retinal Diseases*
2nd Annual Taste of the Islands Eye Conference, Huntington Beach, California; March 26, 2013.
60. *Retinopathy of Prematurity and Eye Care for Infants*
Invited Speaker. Anaheim Regional Medical Center, Anaheim, California; February 21, 2013.
61. *Healthcare*
Invited Speaker. Second Annual Yorba Linda High School Career Day, California; November 1, 2012.

62. *Iontophoretic Dexamethasone Phosphate Ophthalmic Suspension in Patients with Non-Infectious Anterior Segment Uveitis: Phase III Data*
Anaheim, California; October 3, 2012.
63. *Updates in Age-Related Macular Degeneration*
Invited Speaker. Forest Home Conference Center, Forest Falls, California; July 5, 2012.
64. *Update on Retinal Veno Occlusive Diseases*
Guest Speaker (JCAPHO). South Coast Eye Medical Centers, Laguna Hills, California; March 9, 2012.
65. *Healthcare*
Invited Speaker. First Annual Yorba Linda High School Career Day, California; November 8, 2011.
66. *Management of Ophthalmic Emergencies*
Invited Speaker. Forest Home Conference Center, Forest Falls, California; July 5, 2011.
67. *Retinal Disease Management*
Invited Speaker, Fuentes de Gracia Hospital Grand Rounds. Chimaltenango, Guatemala; March 2011.
68. *Diabetes and the Eye*
Invited Speaker. St. Joseph's Hospital, Orange, California; February 26, 2011.
69. *Overcoming Retina Hurdles to 20/20 Vision for Your Patients*
Invited Speaker. Orange County Optometric Society, Western Medical Center, California; August 8, 2010.
70. *Diabetes and the Eye*
Invited Speaker. St. Joseph's Diabetes Day Conference, St. Joseph Medical Center, Orange, California; February 26, 2010.
71. *Retinopathy of Prematurity and Other Ocular Anomalies*
Invited Speaker. Anaheim Regional Medical Center, Anaheim, California; October 27, 2009.
72. Co-Moderator, Day of Ophthalmology. St. Joseph's Hospital, Orange, California; October 3, 2009.
73. *Retinopathy of Prematurity and Neonatal Eye Diseases*
Invited Speaker. Children's Hospital of Orange at Mission Viejo, California; September 28, 2009.
74. *Retinopathy of Prematurity and Neonatal Eye Diseases*
Invited Speaker. Department of Neonatology, Children's Hospital of Orange County, California; July 13, 2009.
75. *Updates in Ophthalmic Care*
Invited Speaker, Fuentes de Gracia Hospital Grand Rounds, Chimaltenango, Guatemala; July 2009.
76. *Updates on New Treatment for Retinal Diseases*
Invited Speaker. TLC Annual Symposium, Anaheim, California; June 7, 2009.
77. *Macular Degeneration*
Invited Speaker, Foundation for Fighting Blindness. Low Vision Symposium, Southern California College of Optometry, Fullerton, California; May 9, 2009.
78. *The Refractive Surgery Retinal Evaluation: Pearls and Pitfalls*
Invited Speaker. TLC, Newport Beach, California; April 22, 2009.

79. *Retinal Disease Update*
Invited Speaker. Fuentes de Gracia Hospital Grand Rounds, Chimaltenango, Guatemala.
August 8, 2008.
80. *Emerging Treatment Strategies for Exudative AMD*
Novartis Speaker Program. Costa Mesa, California; March 12, 2008.
81. *Emerging Treatment Strategies for Exudative AMD*
Novartis Speaker Program. Newport Beach, California; February 20 2008.
82. *Retinopathy of Prematurity and Other Ocular Anomalies*
Invited Speaker. Children's Hospital of Orange at Mission. Mission Viejo, California; February 20, 2007.
83. *Toxoplasma Uveitis*
Invited Speaker, Continuing Medical Education Lecture. Children's Hospital of Orange County, Orange, California; October 23. 2006
84. *Retinopathy of Prematurity*
Invited Speaker. Anaheim Regional Medical Center, Anaheim, California; March 14, 2006.
85. *Retinopathy of Prematurity and Neonatal Eye Diseases*
Invited Speaker. Hoag Presbyterian Hospital, Newport Beach, California; July 12, 2005.
86. *The Great Debates: Controversies in Retinal Disease 2005*
Invited Speaker, Medical Education Seminar. University of California, Irvine, Beckman Laser Center, Irvine, California; March 26, 2005.
87. *Pediatrics Case Conference*
Invited Speaker. Rhode Island Hospital, Providence, Rhode Island; January 20, 2003.
88. *Advances in Retina*
Rhode Island Eye Institute, Providence, Rhode Island; 2002.
89. *Posterior Segment*
Posterior Segment Rounds, Central Oregon Optometric Association, Redmond, Oregon; 2001.
90. *Medicine 2000*
Oregon Society of Medical Assisting Conference, Eugene, Oregon; 2000.
91. *Retinal Diagnoses*
Pacific Northwest Conference, Bend, Oregon; 2000.
92. *Retinal Surgery throughout the Ages*
Lane County Optometric Society Meeting, Eugene, Oregon; 1999.
93. **You TT** and Arroyo JG. Surgical approaches to dislocated lenses. Annual Fellows' Conference, Massachusetts Eye & Ear Infirmary, Boston, Massachusetts; 1998.
94. **You TT** and Young LHY. "Retinal Manifestations of Gastrointestinal Disorders." Biennial Residents' Conference. Massachusetts Eye & Ear Infirmary, Boston, Massachusetts; 1997.
95. **You TT**, R.N. Hogan, C.S. Foster, C.H. Dohlman. "Corneal Injury in Stevens-Johnson Syndrome." Contact Lens Association of Ophthalmologists Meeting, Las Vegas, Nevada; 1997. Poster

96. **You TT**, Hogan RN, Yuhan KR, Foster CS, C.H. Dohlman. "A Clinicohistopathologic Study of Cornea in Erythema Multiforme Major." Academy of Ophthalmology Meeting, Chicago, Illinois; 1996. Poster
97. **You TT**, Hogan RN, Foster CS, Dohlman CH. "Keratopathy in Stevens-Johnson Syndrome: Histopathologic Study of Diseased Cornea." Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida; 1996. Poster
98. **You TT** and Pavan-Langston D. "Sterile Inflammatory Reactions in Herpes Keratitis." Biennial Residents' Day Conference. Massachusetts Eye & Ear Infirmary, Boston, Massachusetts; 1995.
99. Navon S, **You TT**, Chynn EW. "Eye Examination." NPACE Skills Building Seminar, Framingham, Massachusetts; 1995.
100. *Cognitive Decision Making - A Computer Based Model*
Society of General Internal Medicine Meeting, Washington, DC; 1994.
101. **You TT**, Partington MA, Whitaker LA. "Congenital Torticollis and Plagiocephaly: Clinically Frequent Association." 51st American Cleft Palate and Craniofacial Association Conference, Toronto, Canada; 1994.
102. *Bacterial Utilization of Dissolved Organic Matter in a Natural, Oligotrophic Aquatic System*
California Academy of Science Meeting, Los Angeles, California; 1981.

ACTIVITIES

- Baja California Medical Missions Project. Open Doors Orphanage. La Mision, Baja California. February 2015.
- Team Leader, Chimaltenango Medical Missions, Guatemala. September 2016.
- Team Leader. Chimaltenango Medical Missions, Guatemala. March 2017.
- Cambodia Medical Missions. Phnom Penh. Cambodia, May 2017.
- Team Leader. Ophthalmology Medical Missions, Guatemala. May 2018.
- Team Leader. Ophthalmology Medical Missions, Santiago, Guatemala. February 2019.